ACAD
36.86
-0.58
-1.55%
AEMD
6.44
+0.04
+0.64%
APRI
0.311
-0.01
-3.0275%
ARNA
1.7
-0.01
-0.5906%
ATEC
0.38
+0.02
+5.4985%
CNAT
2.32
-0.02
-0.85%
CRXM
0.175
0.00
0.00%
CYTX
2.012
-0.018
-0.8818%
DXCM
89.28
+0.62
+0.70%
GNMK
10.07
-0.03
-0.30%
HALO
9.825
-0.105
-1.057%
ILMN
165.14
+2.89
+1.78%
INNV
0.54
+0.04
+8.93%
INO
9.65
0.00
-0.0010%
ISCO
2
+0.07
+3.63%
ISIS
57.56
0.00
0.00%
LGND
135.68
-0.39
-0.29%
LPTN
2.061
-0.019
-0.9279%
MBVX
0.63
0.00
0.00%
MEIP
1.39
+0.01
+0.72%
MNOV
5.97
-0.12
-1.97%
MRTX
4.705
-0.135
-2.789%
MSTX
0.363
-0.002
-0.6027%
NBIX
50.37
-0.45
-0.89%
NUVA
61.58
+0.93
+1.53%
ONCS
1.78
+0.06
+3.49%
ONVO
4.25
-0.08
-1.85%
OREX
3.4
-0.1
-2.86%
OTIC
14.5
-0.28
-1.89%
QDEL
22.55
+1.5
+7.13%
RCPT
231.96
0.00
0.00%
RGLS
3.705
-0.395
-9.634%
RMD
65.04
-0.09
-0.14%
SPHS
5.354
+0.244
+4.775%
SRNE
6.1
-0.11
-1.77%
TROV
5.72
+0.03
+0.53%
VICL
4.21
+0.01
+0.24%
VOLC
18
0.00
0.00%
ZGNX
9.005
-0.095
-1.044%
ACAD
36.86
-0.58
-1.55%
AEMD
6.44
+0.04
+0.64%
APRI
0.311
-0.01
-3.0275%
ARNA
1.7
-0.01
-0.5906%
ATEC
0.38
+0.02
+5.4985%
CNAT
2.32
-0.02
-0.85%
CRXM
0.175
0.00
0.00%
CYTX
2.012
-0.018
-0.8818%
DXCM
89.28
+0.62
+0.70%
GNMK
10.07
-0.03
-0.30%
HALO
9.825
-0.105
-1.057%
ILMN
165.14
+2.89
+1.78%
INNV
0.54
+0.04
+8.93%
INO
9.65
0.00
-0.0010%
ISCO
2
+0.07
+3.63%
ISIS
57.56
0.00
0.00%
LGND
135.68
-0.39
-0.29%
LPTN
2.061
-0.019
-0.9279%
MBVX
0.63
0.00
0.00%
MEIP
1.39
+0.01
+0.72%
MNOV
5.97
-0.12
-1.97%
MRTX
4.705
-0.135
-2.789%
MSTX
0.363
-0.002
-0.6027%
NBIX
50.37
-0.45
-0.89%
NUVA
61.58
+0.93
+1.53%
ONCS
1.78
+0.06
+3.49%
ONVO
4.25
-0.08
-1.85%
OREX
3.4
-0.1
-2.86%
OTIC
14.5
-0.28
-1.89%
QDEL
22.55
+1.5
+7.13%
RCPT
231.96
0.00
0.00%
RGLS
3.705
-0.395
-9.634%
RMD
65.04
-0.09
-0.14%
SPHS
5.354
+0.244
+4.775%
SRNE
6.1
-0.11
-1.77%
TROV
5.72
+0.03
+0.53%
VICL
4.21
+0.01
+0.24%
VOLC
18
0.00
0.00%
ZGNX
9.005
-0.095
-1.044%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.